**To the Editor:** Borreliosis caused by *Borrelia miyamotoi* is an emerging disease transmitted by *Ixodes* ticks ([@R1]). Each year in the Netherlands during 2007--2009, ≈70,000 bites by hard ticks occurred per 1 million inhabitants ([@R2]). In the Republic of Udmurtia, Russia, ≈10,000 hard tick bites per 1 million inhabitants are reported annually among persons seeking medical help. Recent studies indicate that almost 3% of *I. ricinus* ticks in the Netherlands and 2%--6% of *I. persulcatus* ticks in Russia are infected with *B. miyamotoi* ([@R1],[@R3],[@R4]). Human exposure is substantial, and comparable exposure to *B. miyamotoi* is expected in many Eurasian countries and in North America ([@R4],[@R5]). The probability of *B. miyamotoi* transmission from ticks to humans requires examination to estimate the true risk for human disease.

In Izhevsk (population 650,000), a city in European Russia (Republic of Udmurtia), we identified 95 human cases of *B. miyamotoi* infection during 2010--2014 ([@R6]). In this city, primarily because of concern about tickborne encephalitis (TBE), all patients with suspected tickborne infection are hospitalized in the Republican Hospital of Infectious Diseases (RHID). A service also enables tick-bitten persons to bring the removed tick for PCR for TBE virus (TBEV) and *B. burgdorferi* sensu lato. We supplemented that with PCR testing for *B. miyamotoi* ([@R3]).

In June 2014, twenty-four persons (≈5% of those bitten by ticks subjected to PCR-based investigation for TBEV, *B. burgdorferi* sensu lato, and *B. miyamotoi*) were bitten by adult *I. persulcatus* ticks infected with *B. miyamotoi* only. We informed these persons of their results and about the clinical features of *B. miyamotoi* infection and recommended self-observation during 2 months (twice the maximum incubation period for *B. miyamotoi* infection \[[@R3],[@R6]\]). These persons were advised to contact their medical supervisor at RHID (D.S. Sarksyan) if fever, fatigue, erythema migrans, or any other possible symptom of a tickborne infection developed. In 2 patients, such symptoms developed: one 12 days (patient 1), the other 16 days (patient 2), after the tick bite. *B. miyamotoi* DNA was detected by PCR in their blood on admission to RHID. Neither IgM nor IgG were found by a nonspecific ELISA (Omnix, St. Petersburg, Russia \[[@R7]\]) that reacts with serum from *B. burgdorferi* sensu lato--infected and *B. miyamotoi*--infected persons. However, *Borrelia* IgM and IgG were detected in serum obtained 12 and 45 days after illness onset from patient 1 and 6 and 39 days later from patient 2. Clinical characteristics were typical of *B. miyamotoi* infection: chills, sweating, headache, dizziness, fatigue, thirst, nausea, vomiting, fever (axillar temperature 38.8°C in patient 1 and 39.0°C in patient 2). Erythema migrans was absent. Both patients had modest thrombocytopenia (134 \[patient 1\] and 118 \[patient 2\] × 10^9^ platelets/mL \[reference range 150--400 × 10^9^ platelets/mL\]) and increased band neutrophils (10% \[patient 1\] and 8% \[patient 2\] of leukocytes \[reference range 1%--5%\]). Patient 2 had clinical and laboratory signs of kidney dysfunction (oliguria, leukocytes, erythrocytes, and epithelial cells in a urine sample), a complication observed in 18% of 95 patients with *B. miyamotoi* disease ([@R4]). Both patients were treated with doxycycline (100 mg 2×/d) for 10 days; they clinically recovered, and laboratory abnormalities returned to reference ranges at discharge 12 days after admission.

The remaining 22 persons did not report any malaise and were examined 1 month after tick bite. They appeared healthy at that time, and PCR and ELISA gave negative results, arguing against possible asymptomatic *B. miyamotoi* infection.

We estimated the probability of *B. miyamotoi* transmission to humans to be 8.3% (95% CI 4%--18% using a Bayesian approach \[[@R8]\] or 95% CI 0%--21% using an SPSS bootstrapping procedure \[SPSS Inc., Chicago, IL, USA\]). For comparison, among 68 persons bitten by *B. burgdorferi* sensu lato--infected ticks in the Netherlands, erythema migrans developed in 4.4% (95% C.I. 2.1%--8.3%) persons; 3 (4.4%) others seroconverted without clinical symptoms ([@R9]).

This pilot study has several limitations. We did not follow up persons bitten by *B. burgdorferi* sensu lato-- or TBEV-infected ticks because they received either antimicrobial drugs or anti-TBE immunoglobulin as a preventive measure. Because of labor constrains, we did not study persons bitten by "PCR-uninfected" ticks; however, they were not hospitalized at RHID, the only hospital in the region for patients with evident tick-borne diseases. We did not use any serologic techniques specific for relapsing fever *Borreli* (e.g., GlpQ ELISA). Although we did not test for *Rickettsia* or *Babesia* spp., we did not find TBEV RNA, *B. burgdorferi* sensu lato 16S RNA, pathogenic *Ehrlichia* 16S RNA, or pathogenic *Anaplasma* DNA in the 2 *B. miyamotoi*--positive patients' blood samples.

We demonstrated that the transmission rate of *B. miyamotoi* appears to be equal to, or higher, than that of *B. burgdorferi* sensu lato ([@R1],[@R9],[@R10]). Our data indicate that, annually, clinical *B. miyamotoi* infection might develop in at least 0.005% of persons living in regions to which *Ixodes* spp. ticks and *B. miyamotoi* are endemic. This estimate corresponds to ≈33 cases annually in Izhevsk, which is similar to the previously published results of hospital-based surveillance for *B. miyamotoi* ([@R3],[@R6]).
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